Get Your Personalized Supplement StackSupplement Stack Quiz

Cinchona officinalis

Also known as: Peruvian bark, Jesuit's bark, Cinchona bark, Cinchona officinalis

Overview

Cinchona officinalis, commonly known as Peruvian bark, is a plant native to the Andean region of South America. It is historically renowned for its potent antimalarial properties, primarily attributed to the presence of quinoline alkaloids, most notably quinine. The bark has been extensively used for centuries in traditional medicine to treat fever and malaria. Beyond its established antimalarial use, contemporary research is exploring its potential in other therapeutic areas, including anticancer, antiviral, and antifungal applications. While its antimalarial efficacy is well-documented and supported by strong evidence, the research for its other potential uses is still emerging and requires further clinical validation. The plant is characterized by its rich content of various quinoline alkaloids, such as quinine, quinidine, cinchonine, and cinchonidine, which are responsible for its diverse pharmacological activities. It is typically consumed in the form of bark extracts or isolated alkaloids.

Benefits

The primary and most well-documented benefit of Cinchona officinalis is its antimalarial efficacy, which is considered strong and clinically significant. Historically, it has been a cornerstone in the treatment of malaria, particularly in tropical regions where the disease is endemic. Recent studies suggest potential anticancer effects, with research indicating activity against various cancer cell lines, including breast cancer (MCF-7) and lung cancer (A-549). While promising, these findings are largely preclinical and require extensive clinical validation to confirm their relevance in human cancer treatment. Additionally, Cinchona officinalis has shown antiviral activity, with in vitro studies reporting significant growth inhibition against SARS-CoV-2. However, this evidence is also preliminary and human trials are necessary to ascertain its effectiveness against viral infections in vivo. The immediate antimalarial effects are well-established, while the long-term benefits for other emerging uses are less clear and subject to ongoing research.

How it works

The primary mechanism of action of Cinchona officinalis, particularly its quinoline alkaloids like quinine, involves interfering with heme detoxification in malaria parasites. This disruption leads to the accumulation of toxic heme, ultimately killing the parasite. In the context of potential anticancer effects, these alkaloids are thought to inhibit cancer cell proliferation through various pathways, though the exact mechanisms are still under investigation. Cinchona alkaloids primarily interact with the body's immune and circulatory systems. Quinine is well-absorbed orally, but its bioavailability can vary. Its molecular targets are primarily the heme detoxification pathways within the malaria parasite, which is crucial for its antimalarial efficacy.

Side effects

When used appropriately for malaria, Cinchona officinalis is generally considered safe, but potential risks exist, especially with long-term or high-dose use. Common side effects include gastrointestinal upset, headache, and dizziness. Less common but notable side effects include allergic reactions and a syndrome known as 'cinchonism,' characterized by symptoms such as tinnitus (ringing in the ears) and blurred vision. Rare but severe side effects can include severe allergic reactions and thrombocytopenia (a decrease in platelet count). Cinchona officinalis may interact with certain medications, including anticoagulants (blood thinners) and some antibiotics, potentially altering their effects or increasing the risk of adverse reactions. It is contraindicated in pregnant and breastfeeding individuals due to potential risks to the fetus or infant. Caution is also advised for individuals with certain cardiac conditions, as it can affect heart rhythm, and in children. Monitoring for side effects and drug interactions is crucial during its use.

Dosage

For its established antimalarial use, the typical minimum effective dose of quinine from Cinchona officinalis is generally around 500-1000 mg per day. The optimal dosage ranges for antimalarial treatment vary, but commonly fall between 500-2000 mg per day, depending on the specific condition and patient factors. The maximum safe dose for non-antimalarial uses is not yet well-defined due to limited clinical research in these areas. Cinchona preparations are typically taken with meals to help reduce gastrointestinal side effects, which are common. Common forms include capsules or tablets. Absorption of the active compounds, particularly quinine, can be influenced by food intake. There are no specific cofactors identified as required for its efficacy. It is crucial to consult a healthcare provider for appropriate dosing, especially for non-antimalarial applications, and to adhere to prescribed guidelines to ensure safety and efficacy.

FAQs

Is Cinchona officinalis a proven cure for cancer or viral infections other than malaria?

No, while preliminary research shows potential anticancer and antiviral activity in lab settings, it is not a proven cure for cancer or viral infections beyond malaria. More human clinical trials are needed to confirm these benefits.

How should I take Cinchona officinalis to minimize side effects?

To minimize gastrointestinal side effects, it is generally recommended to take Cinchona officinalis preparations with meals. Always follow specific dosing instructions from a healthcare professional.

What are the most important safety considerations when using Cinchona officinalis?

Key safety considerations include monitoring for side effects like cinchonism, being aware of potential drug interactions with anticoagulants and certain antibiotics, and avoiding use during pregnancy, breastfeeding, or with certain heart conditions.

What is 'cinchonism' and what are its symptoms?

Cinchonism is a syndrome that can occur with Cinchona use, characterized by symptoms such as tinnitus (ringing in the ears), blurred vision, headache, dizziness, and gastrointestinal upset. It indicates a need to adjust dosage or discontinue use.

Research Sources

https://pmc.ncbi.nlm.nih.gov/articles/PMC9565860/ – This source provides a comprehensive review of the pharmacological activities of quinoline alkaloids from Cinchona species. It highlights their established antimalarial properties and explores emerging potential in treating various diseases, including cancer and fungal infections. The review emphasizes that while preclinical evidence is promising for new applications, rigorous human studies are necessary to establish clinical efficacy and safety.
https://biointerfaceresearch.com/wp-content/uploads/2022/09/BRIAC134.319.pdf – This study investigated the anticancer effects of Cinchona alkaloids against various cancer cell lines, specifically mentioning activity against MCF-7 (breast cancer) and A-549 (lung cancer). The findings suggest a potential role for Cinchona in cancer treatment, but the research is preclinical, indicating a need for further clinical trials to validate these effects in humans.
https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0043-1770339.pdf – This research explored the antiviral activity of Cinchona officinalis, specifically demonstrating significant in vitro growth inhibition (approximately 89%) against SARS-CoV-2. While the results are promising for its potential as an antiviral agent, the study was conducted in vitro, meaning human trials are essential to confirm its efficacy and safety in treating viral infections in living organisms.